The FDA recently approved the use of Bemotrizinol in sunscreens, making it the first new sunscreen filter approved in the United States in more than 25 years. While consumers in Europe have had access to this ingredient since 1999, it has only now become available for use in U.S. sunscreen products.
As a skin cancer surgeon, Dr. Mikhail Novikov welcomes the news.
“It covers both UVA and UVB rays in a single molecule, it’s more photostable than our current chemical filters, and it goes on clear without a white cast,” Dr. Novikov explained. “That last point isn’t cosmetic trivia. The best sunscreen is the one people actually wear every day, and texture is one of the biggest reasons patients tell me they skip it.”
For patients, the potential benefits are significant. Better stability means longer-lasting protection, broader coverage helps defend against both skin cancer and premature aging, and improved cosmetic feel may encourage more consistent daily use.
But Dr. Novikov cautions that no new ingredient changes the fundamentals of skin cancer prevention.
“You still need to reapply sunscreen every two hours when outdoors, seek shade when possible, wear protective clothing, and schedule an annual skin examination,” he said.
“Most of the skin cancers I remove could have been prevented—or detected much earlier. That’s why routine skin checks remain just as important as sunscreen.”
The approval of Bemotrizinol is an encouraging step forward and may pave the way for additional modern sunscreen filters in the future. But regardless of which sunscreen you choose, the goal remains the same: consistent sun protection and early detection.
Because when it comes to skin cancer, prevention and early diagnosis still matter more than any single ingredient.